Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN2176-3 · 1 trial · 1 indication
The primary endpoint in the study is the incidence of treatment emergent adverse events (TEAEs) from day 1 through week 24 in patients treated with IVT REGN2176-3.
| Arm | Type | Description |
|---|---|---|
| Cohorts 1 - 4 | EXPERIMENTAL | Participants in cohort 1 will receive REGN2176-3 dosing regimen 1. Participants in cohort 2 will receive REGN2176-3 dosing regimen 2. Participants in cohort 3 will receive REGN2176-3 dosing regimen 3. Participants in cohort 4 will receive REGN2176-3 dosing regimen 4. |
| Name | Type | Description |
|---|---|---|
| REGN2176-3 | DRUG | - |
Inclusion Criteria: Key Criteria: Men or women greater than or equal to 50 years of age who provide informed consent and have active subfoveal choroidal neovascularization (CNV) secondary to wet AMD. Exclusion Criteria: 1. Any prior treatment with an inhibitor of PDGF (platelet-derived growth fa...
REGN2176-3 is an investigational small molecule being developed for the treatment of neovascular wet age-related macular degeneration (AMD), a condition that causes abnormal blood vessel growth in the eye leading to vision loss. It is administered via intravitreal injection and is currently in Phase 1 clinical development.
REGN2176-3 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol REGN. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational therapy for wet AMD.
REGN2176-3 is in Phase 1 clinical development. A Phase 1 safety study has been completed, and the drug remains investigational, meaning it has not been approved by regulatory authorities. Further clinical trials would be needed to establish its safety and efficacy for wet AMD.
REGN2176-3 has been studied in one clinical trial, identified as NCT02061865. This was a Phase 1 safety study conducted in the United States with 12 participants aged 50 years and older with wet AMD. The trial has been completed and was not randomized or double-blinded.
REGN2176-3 is administered via intravitreal injection, meaning it is injected directly into the vitreous humor of the eye. This route of administration is commonly used for treatments targeting retinal diseases like wet age-related macular degeneration to deliver the drug locally to the affected tissue.